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Abstract
Tissue engineering-based bone graft is an emerging viable treatment modality to repair
and regenerate tissues damaged as a result of diseases or injuries. The structure and
composition of scaffolds should modulate the classical osteogenic pathways in human
stem cells. The osteoinductivity properties of the hydroxylapatite-collagen hybrid scaf-
fold named Coll/Pro Osteon 200 were investigated in an in vitro model of human adi-
pose mesenchymal stem cells (hASCs), whereas the clinical evaluation was carried out in
maxillofacial patients. Differentially expressed genes (DEGs) induced by the scaffold
were analyzed using the Osteogenesis RT2 PCR Array. The osteoinductivity potential of
the scaffold was also investigated by studying the alkaline phosphatase (ALP) activity,
matrix mineralization, osteocalcin (OCN), and CLEC3B expression protein. Fifty patients
who underwent zygomatic augmentation and bimaxillary osteotomy were evaluated clin-
ically, radiologically, and histologically during a 3-year follow-up. Among DEGs,
osteogenesis-related genes, including BMP1/2, ALP, BGLAP, SP7, RUNX2, SPP1, and
EGFR, which play important roles in osteogenesis, were found to be upregulated. The
genes to cartilage condensation SOX9, BMPR1B, and osteoclast cells TNFSF11 were
detected upregulated at every time point of the investigation. This scaffold has a high
osteoinductivity revealed by the matrix mineralization, ALP activity, OCN, and CLEC3B
expression proteins. Clinical evaluation evidences that the biomaterial promotes bone
regrowth. Histological results of biopsy specimens from patients showed prominent ossi-
fication. Experimental data using the Coll/Pro Osteon 200 indicate that clinical evalua-
tion of bone regrowth in patients, after scaffold implantation, was supported by DEGs
implicated in skeletal development as shown in “in vitro” experiments with hASCs.
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1 | INTRODUCTION
Bone fractures/injuries can have a highly deleterious impact on patients'
quality of life. Therefore, understanding the mechanisms of bone repair is
important for both the patients' health and economy. Tissue engineering–
based bone grafts are emerging as a viable treatment to repair and
regenerate tissues damaged as a result of diseases. The structure and com-
position of scaffolds stimulate the classical osteogenic pathways through
an active process which occurs inmesenchymal stem cells (MSCs). Investi-
gators are facing a great challenge to design and develop suitable scaffold
materials with biological activities for the tissue regeneration in transla-
tional and precise medicine. Tissue-engineered approaches to regenerate
bone in the craniomaxillofacial region utilize scaffolds to provide structural
and biological cues to stem cells to stimulate osteogenic differentiation.
The repair and regrowth of craniofacial tissues are particularly challenging,
because they form a complex structure which is composed of hard and
soft tissues involved in complex biological functions. Porous hydroxylapa-
tite/collagen (HA/Coll) composite biomaterials are suitable for bone
grafting, as well as for bone regeneration.1,2
The biomaterial known as Pro Osteon 200 is a coral derived
porous HA, which is available in granule and block forms. This scaffold
has been shown to be highly biocompatible in cellular3-5 and animal
models,6-8 and in some clinical applications.9 Scaffolds used for the
bone regrowth can be assayed for specific features, such as osteo-
inductivity, osteoconductivity, and biocompatibility proprieties. Little
is known about biological features and gene induction occurring after
biomaterial adding.
In the past decade, significant studies have been carried out using
human adipose-derived stromal/stem cells (hASCs) in the bone tissue
engineering regeneration/regrowth10 and tooth periodontal regenera-
tion.11 hASCs are a type of adult MSCs capable of self-renewal and dif-
ferentiation toward osteogenic, chondrogenic, and adipogenic.12-14
Indeed, these cells own a multilineage differentiation capacity that is reg-
ulated through extracellular signals. The cellular events related to cell
adhesion and cytoskeleton organization have been suggested as central
regulators of differentiation fate decision. Little is known about the
molecular mechanisms which allow hASCs to differentiate.15 Since the
discovery of the hASCs induced-osteogenesis, many studies substantially
contributed the knowledge of hASC cell biology and their use as a cell
source for bone regeneration.16 Ideal scaffolds, for hASC bone tissue
engineering strategies, should be biocompatible and capable of
supporting stem cells growth and differentiation, while providing predict-
able mechanical and degradation properties during the healing process.
In the present study, new investigations were carried out to evalu-
ate the biocompatibility and osteoinductivity properties of the HA-
Coll hybrid scaffold in an “in vitro” model of hASC and in patients
undergoing orthognathic surgical procedures associated with malar
augmentation. The cellular biology, molecular genetic and epigenetic
experiments were carried out by RT-qPCR Array and protein expres-
sion, such as osteocalcin (OCN) and alkaline phosphatase (ALP) by
immunostaining and ELISA approaches, respectively. The osteogene-
sis potential of cells was also investigated to verify the matrix
mineralization by Alizarin-Red S staining. The biocompatibility of the
material was evaluated by cellular viability, morphology, and cytoskel-
eton architecture, in hASCs grown on the hybrid scaffold.
In a previous study17 gene expression analyses by RT-PCR technol-
ogy were carried out at early times post-cell seeding on biomaterial. To
this end, mRNAs extracted from cells, hASCs, were comparatively ana-
lyzed by RT-PCR at days 3 and 9. hASCs were grown on the scaffold,
and plastic vessel (TCPS), used as control. PCR technology demonstrated
that biomaterial induces in hASCs upregulation of specific genes, such as
SPP1 and CLEC3B, which are involved in bone mineralization and ossifi-
cation processes, at days 3 and 9 post-cell seeding. In addition, in our
experimental conditions, ALP, ON, CHAD, SP7, and Sox9 genes had a
higher expression compared with hASCs grown on TCPS, at day 3 post-
seeding.
In the present study, in order to mimic the long period needed
“in vivo” by the bone to regrowth/repair/healing, the experiments
were carried out up to day 40.
Patients operated for maxillomandibular malocclusion and/or
asymmetry, or for aesthetic reasons, who underwent malar augmenta-
tion with porous HA/Coll prostheses (hybrid scaffold), were evaluated
for the new bone formation during a 3-year period of follow-up using
radiological and histological analyses.
The strength of this article is the combination of in vitro and
in vivo evaluations of HA-Coll hybrid scaffold on osteoinductivity and
bone regrowth proprieties. In hASCs grown on biomaterial, RT2 Pro-
filer PCR array “Human Osteogenesis” approach allowed us to analyze
the epigenetic profiles of 84 genes belonging to the osteogenetic
pathway, at two experimental time points, days 21 and 40.
2 | MATERIALS AND METHODS
2.1 | Experimental design
Biocompatibility, osteoinduction, and osteoconductivity proprieties of
the innovative scaffold composed by Avitene Microfibrillar Collagen
Significance statement
Bone regrowth can be achieved using different scaffolds. Bio-
materials provide structural and biological cues to stem cells
to stimulate the osteogenic differentiation. The new knowl-
edge on the mechanisms of bone repair is of paramount
importance to address significant steps needed in transla-
tional and precise medicine to cure patients. The hybrid scaf-
fold Pro Osteon200/Avitene Collagen showed a significant
osteogenic induction. The continuous supply of human
adipose-derived mesenchymal stem cells for bone regrowth/
remodeling, chondrogenic, and osteoclast activities with their
epigenetic modulations have been disclosed herein. The new
data of this study indicate that the continuous expression of
osteogenic, osteoclastic, and chondrogenic genes favors bone
regrowth.
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Hemostat and Granular Pro Osteon 200 coralline HA (Coll/Pro
Osteon 200) were analyzed in hASC grown on the scaffold up to day
40. The clinical radiological and histological analyses were performed
on orthognathic surgical patients during a 3-year follow-up (see the
Graphical Abstract).
2.2 | Cell culture
hASCs were purchased from Lonza Milan, Italy (PT-5006) as
cryopreserved frozen cells at the first passage. These cells are positive
for surface markers CD13, CD29, CD44, CD73, CD90, and CD105,
CD166, whereas they are negative for other markers, such as CD14,
CD31, and CD45. Cells were expanded in Dulbecco's Modified Eagle
Medium F-12 (DMEM/F12; Lonza, Milan, Italy), as previously
described.17-19 Primary hASC cultures were grown (i) in the presence
of the osteogenic condition (OC) only17,20; (ii) on the biomaterial Coll/
Pro Osteon 20017; (iii) in the tissue culture polystyrene (TCPS) vessels,
the control.17 Experimental time points were at days 14, 21, and 40 as
indicated for the different assays later in the article.
2.3 | Biomaterial
Porous HA-derived scaffold used herein is composed by Granular Pro
Osteon200 (Interpore Cross Irvine, California) and Avitene Microfibril-
lar Collagen Hemostat (Bard Warwick, Rhode Island) (Coll).9,17 This
scaffold is named Coll/Pro Osteon 200. Granular Pro Osteon 200 is a
coralline HA, which is very similar in its make up to human bone min-
eral composition and form. The manufacturing scaffold using in vitro
and in vivo evaluations was descried before in detail.9,17
2.4 | Osteogenesis RT2 profiler PCR array
To identify genes of the osteogenic pathway activated by the scaffold,
an osteogenesis PCR array was performed, in triplicate, in hASCs
grown on the biomaterial. Specifically, total RNA was isolated through
RNeasy Plus Micro Kit (Qiagen, Milan, Italy) according to the manufac-
turer's instructions from cells grown on (i) Coll/Pro Osteon 200 scaf-
fold and (ii) TCPS (control group). RNA was quantified by using a
Nanodrop spectrophotometer (ND-1000; NanoDrop Technologies,
Wilmington, Delaware).17,21 The Human Osteogenesis RT2 Profiler
PCR Array (Qiagen) was used as described.17,22 Specific primers sets
used in real-time PCRs were used to analyze the expression of
84 genes involved in different pathways, such as osteogenic differen-
tiation, cartilage condensation, ossification, bone metabolism, bone
mineralization, binding to Ca2+ and homeostasis, extracellular matrix
(ECM) protease inhibitors, adhesion molecules, cell-to-cell adhesion,
adhesion molecules of the ECM, and growth factors. For data analysis,
the fold change (FC) of each gene expression was calculated by using
the 2−ΔΔCt method, whereas housekeeping genes, used as controls,
were used to normalize results and Log2 FC; <1 or >1 was considered
significant.17,23
2.5 | Cell differentiation and matrix mineralization
Osteogenic proteins including Tetranectin/CLEC3B expression,17 ALP
activity,17 and OCN expression levels were analyzed in hASCs grown
on scaffold. ALP activity was determined, at day 40, by a colorimetric
Naphthol AS-BI phosphate-based reaction using the Alkaline
Phosphatase Detection Kit (Merck Millipore Corporation, Milan, Italy),
following the manufacturer's indications, as described.17 Alizarin Red
(Sigma, Milan, Italy, A5533) was used to analyze the matrix mineraliza-
tion, as described.17,18 The mineralized substrates were quantified by
using a 20% methanol and 10% acetic acid in a water solution (Sigma-
Aldrich, Milan, Italy).24. To quantify the matrix mineralization, the solu-
tion was transferred into cuvettes, whereas the quantity of Alizarin
red dissolved was read spectrophotometrically (Thermo Electron
Corp., model Multiskan EX, Vantaa, Finland) at a wavelength (λ) of
450 nm. At days 14, 21, and 40, the expression of the OCN, as a pro-
tein, was investigated in hASCs grown in OC, on the biomaterial and
TCPS. The protein was extracted with Cell Extraction Buffer (Catalog
number FNN0011 Thermo Fischer Scientific, Milan, Italy) added with
1 mM phenylmethylsulfonylfluoride and a protease inhibitor cocktail.
The concentration of total protein was determinate by bicinchoninic
acid assay according to manufacturer's instructions.19 The OCN pro-
tein was quantified by the Human Osteocalcin Instant ELISA (Thermo
Fisher Scientific, Milan, Italy) according to the manufacturer's instruc-
tions. Immunostaining was performed for the CLEC3B using the
CLEC3B-specific mouse monoclonal primary antibody (HYB
130-11-02, Thermo Fisher Scientific, Milan, Italy) and an anti-mouse
IgG (whole molecule) secondary antibody-tetramethyl-rhodamine-
isothiocyanate (TRITC), diluted in saline with 0.1% bovine serum
albumin.17
2.6 | Cell viability and cytoskeleton architecture
Viability of hASCs grown on the biomaterial was evaluated by fluores-
cent microscopy analysis using hASCs transfected with an adenovirus
(Ad) vector expressing the green fluorescence protein (eGFP),17,25
hASCs-eGFP. Cytoskeletal actin filaments of hASCs-eGFP were sta-
ined with TRITC-conjugated Phalloidin (Sigma, Milan, Italy) as previous
descried at days 14, 21, and 40.17-19
2.7 | Scanning electron microscopy analysis
Biomaterial with and without cells was analyzed by scanning electron
microscopy (SEM; Cambridge UK, model Stereoscan S-360).17 Sam-
ples were washed with saline; then fixed for 1 hour by 2.5% glutaral-
dehyde and additional 4 hours with a 1% osmium solution in
phosphate buffer. Then, the biomaterial was coated with colloidal gold
and SEM analyzed.17,18
2.8 | Fluorescent and confocal microscope analyses
Fluorescent images were taken using a TE2000E fluorescence micro-
scope. Digital images were captured using ACT-1 and ACT-2 software
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for DXM1200F digital cameras (Nikon S.p.A., Florence, Italy). Nuclei were
stained with 0.5 mg/mL 4,60-diamino-2-phenylindole (DAPI).26,27 Digital
images of cellular morphology were acquired with confocal microscope
(LSM510; Carl Zeiss, Jena, Germany) using a 10 × 1.4 NA Plan-
Apochromat oil-immersion objective and equipped with ZEN microscope
imaging software (Zeiss Instruments). The background of acquired
images were corrected, whereas signals were analyzed using the open
source Fiji software (http://fiji.sc/Fiji).
2.9 | Bone regrowth evaluated in maxillofacial
patients
The treatment plan, which aimed to achieve functional and esthetic
improvement, was to enhance the malar area of patients with inade-
quate cheekbone projection or facial asymmetry. All orthognathic sur-
gical procedures were carried out as previously described9 in the
Arnett-Gunson Center for Corrective Jaw Surgery (Santa Barbara, Cal-
ifornia) or at the Maxillofacial Surgery Unit of the University of
Verona Medical Center (Verona, Italy).9Over a 3-year period
(2016-2018), 50 patients (25 women and 25 men; mean age,
28 years; range, 18-45 years, total 100 prosthesis) underwent malar
augmentation procedures using the hybrid scaffold Collagen/Pro
Osteon to optimize facial esthetics. The follow-up time was 3 years.
This study was approved by the Institutional Review Board of the
Verona Hospital (Verona, Italy). All patients signed an informed writ-
ten consent agreement. The present study followed the Declaration
of Helsinki on medical protocol.
2.9.1 | Radiologic imaging
CT scans taken 1 month (T1) and 24 months (T2) after surgery were
available for all patients. Signs of resorption of native bone and var-
iations in the structure and radiopacity of the implanted prosthetic
material were evaluated by an observer, in a blind manner (the radi-
ologist who analyzed the cone-beam computed tomography—
CBCT). Twenty of 50 patients also agreed to undergo a CBCT
(NewTom 3G device; QR srl, Verona, Italy) at least 36 months after
surgery (T3).
2.9.2 | Histology
Biopsy samples were obtained from implants in three patients who
required plates removal at maxillae level 2 years after surgery. The
material collected was treated as described.9 Morphologic and immu-
nohistochemical analyses of bone samples were performed to evalu-
ate remodeling and osteogenetic process. Four-micrometer-thick
sections were stained with hematoxylin and eosin, and immunohisto-
chemistry was performed on subsequent sections using two monoclo-
nal antibodies specific for cathepsin K (clone CK4, Novocastra,
Newcastle, UK; clone 3F9, Abcam, Cambridge, UK) to stain osteo-
clasts and for CD56 (clone 123C3.D5, 1:100; Thermo Scientific,
Grand Island, New York) to stain osteoblasts, as previously described.9
2.10 | Statistical analysis
Statistical analyses of experiments, performed in triplicate, were
carried out by using Prism 6 (GraphPad Software, La Jolla,
California),23,28,29 one-way analysis of variance with Dunnett's
posttest analysis and Student's t test. A value of P-value <.05 was
considered significant.
3 | RESULTS
3.1 | In vitro and in vivo evaluations
Biocompatibility, osteoinductivity, and osteoconductivity properties
of the innovative scaffold composed by Avitene Microfibrillar Colla-
gen Hemostat and Granular Pro Osteon 200 coralline HA (Coll/Pro
Osteon 200) were analyzed in hASC grown on the scaffold up to day
40. The clinical radiological and histological analyses were performed
on orthognathic surgical patients during a 3-year follow-up (see
Graphical Abstract for more details).
3.2 | Scaffold modulates the DEGs implicated in
skeletal development
In a previous study, we investigated in a short period of time few
specific osteogenic genes, such as ALP, Osteonectin, Transcription
factor Osterix, SP7 and CLEC3B, which were reported upregulated
in hASCs grown on the scaffold, at day 9 (24). Herein, RT2 Profiler
PCR array was used to analyze the expression of osteogenic genes.
The gene expression was evaluated in hASCs grown on Coll/Pro
Osteon200 compared with TCPS, at days 21 and 40. A total of
31 differentially expressed genes (DEGs) including 22 upregulated
genes (red), 7 downregulated genes (green), and 2 genes which were
upregulated (day 21) and then downregulated (day 40), were identi-
fied in hASCs grown on the biomaterial (Figure 1A, B; Tables S1
and S2). Among DEGs, osteogenesis-related genes, including the
Bone Morphogenetic Protein 1/2 (BMP1/2), ALP, Bone Gamma-
Carboxyglutamate Protein (BGLAP), transcription factor Sp7 (SP7),
Runt-related transcription factor 2 (RUNX2), Secreted Phosphopro-
tein 1 (SPP1), Collagen type I alpha 1 (COL1A1), epidermal growth
factor receptor (EGFR), which play important roles in osteogenesis,
were found to be upregulated at day 21. Moreover, the transcription
factor condensation SRY (sex-related Y)-type high mobility group
box SOX-9 (Sox9), and BMPR1B which plays a central role in chon-
drocyte differentiation, were also found to be upregulated, on hASCs
grown on the scaffold, at days 21 and 40. Real-Time qRT-PCR rev-
ealed increased expression of the receptor activator of nuclear factor
kappa-Β ligand (RANKL), also known as tumor necrosis factor ligand
superfamily member 11 (TNFSF11) at days 21 and 40. The growth
factors, such as the colony-stimulating factor 2/3 (granulocyte-mac-
rophage) (CSF2/3), and epidermal growth factor (EGF), were also
found to be upregulated at days 21 and 40. The heat map, shown in
Figure 2, provides a visualization of FCs of expression values among
genes, in the array in the context of the array layout. hASCs grown
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on the biomaterial DEGs downregulated were n = 1 at day 21 and
n = 9 at day 40. Genes encoding for cell-ECM, adhesion molecules
such as CD36 molecule thrombospondin receptor (CD36), Cartilage
oligomeric matrix protein (COMP), and Integrin, alpha M comple-
ment component 3 receptor 3 subunit (ITGAM) were downregulated
at day 40. The list of upregulated and downregulated genes at days
21 and 40 is reported (Table S1, Table S2), respectively.
3.3 | Scaffold induces the matrix mineralization and
osteogenic expression proteins in hASCs
Recently, we reported a significant increase of matrix mineraliza-
tion and ALP activity in hASCs grown on the biomaterial, at day
21.17 In the present investigation, the osteoinductive activity of the
biomaterial is highlighted by the matrix mineralization detected in
hASCs grown on the scaffold at day 40. Indeed at day 40, the
F IGURE 1 PCR array analyses of osteogenic genes. The gene expression was evaluated in human adipose mesenchymal stem cells grown on
Coll/Pro Osteon200 compared with tissue culture polystyrene. A, Induced genes at day 21. In hASC cultures, mRNAs of 22 genes of the
osteogenic pathway, that is, ALPL BGLAP BMP1/2, BMPR1B, COL1A1,CSF2/3, EGFR, FGFR1, FGFR2, IGF1, IGF1R, NOG,RUNX2, SOX9, SP7,
SPP1, TGFB1, TNFSF1, TWIST1, and VDR were upregulated; one gene, such as VCAM1 was downregulated. B, Induced genes at day 40. In hASC
culture, mRNAs of 10 genes of the osteogenic pathway, that is, BMP2, BMPR1B, CSF2, CSF3, EGF, EGFR, ITGA2, SOX9, SPP1, and TNFSF11
were upregulated, whereas nine genes were downregulated (BMP6, CD36, COMP FGFR2, IGF2, ITGAM, NOG TGFB3, and VCAM1)
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biomaterial favored the matrix mineralization better than the plas-
tic vessel (TCPS), the control (Figure 3A,C, *P < .05). Moreover, cal-
cium deposits in hASCs grown on OC were higher compared with
cells grown on the biomaterial or TCPS (**P <. 0001; Figure 3A,C).
Cells grown on the biomaterial and in OC showed a significant
increase of the ALP activity compared with TCPS, at day 40
(Figure 3B).
ELISA data show a statistically significant increase of the OCN
protein expression in cells grown on biomaterial, at the three time
points, that is, at days 14, 21, and 40, compared with the control. This
result is in agreement with previous data obtained at day 9.17 The
expression of OCN in hASCs grown on the biomaterial was higher
than in OC/TCPS, at day 14 (*P < .05). The hybrid scaffold influences
the osteogenic pathway at days 21 and 40 compared with TCPS
(*P < .05) (Figure 3D). Cells grown in OC showed higher expression
levels of OCN compared with TCPS at days 14 and 21 (*P < .05)
(Figure 3D).
CLEC3B/tetranectin protein was detected by immunohistochem-
istry in hASCs cultured on scaffold and in OC, at day 40 (Figure 3E),
whereas it was absent in hASCs grown on TCPS (data not shown).
CLEC3B protein, which binds Ca2+, was investigated because of its
potential involvement in the bone mineral metabolism. In hASCs
CD105-enriched cell populations, an increased CLEC3B expression
was detected in response to osteoinduction.30 In an earlier investiga-
tion, the CLEC3B mRNA expression levels tested upregulated at days
3 and 9.17
3.4 | Scaffold is biocompatible in hASCs
hASCs grown on the biomaterial were investigated for their viability,
proliferation, and cytoskeleton organization at days 14, 21, and 40.
hASC-eGFP grown on biomaterial showed a normal cell morphology
(Figure 4A, B, E).17 The biomaterial demonstrated its biocompatibility
up to day 40 in terms of cell adhesion and proliferation. hASC-eGFP
cell morphology was indistinguishable from parental hASCs
(Figure 4A, B, E). The cytoskeleton architecture appeared to be well
organized, whereas its integrity remains uninfluenced by the scaf-
fold, up to day 40 (Figure 4C, E). Actin fibers seem to connect the
cellular membranes and the cytoskeleton to the scaffold surface with
no visible loss or structural displacement. Similar physiologic cyto-
skeleton architecture was observed by confocal microscopy at day
40 (Figure 4D).
3.5 | SEM analysis
SEM analysis was performed to investigate the microstructure and
morphology of the scaffold (Coll/Pro Osteon 200) without hASCs
(Figure 5A) and with cells grown on it, up to day 40 (Figure 5B-F). The
granular HA mixed with collagen fibers creates a highly fibrous struc-
ture. The biomaterial showed a different like-bone structure, in the
presence of cells, at day 40. hASCs grown on the scaffold showed a
normal cell morphology exhibiting pseudopodium-like structures in
tight contact with the ECM (Figure 5F).
F IGURE 2 Graphical representation through heat map of the mRNA expression in human adipose mesenchymal stem cells (hASCs) grown on
Coll/Pro Osteon 200. The fold-change values of upregulated (red) and downregulated (green) genes in hASCs grown on Coll/Pro Osteon
200 compared with the control are reported at day 21 (A) and day 40 (B), respectively. C, Plate scheme of RT2 osteogenic array
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3.6 | Bone regrowth in maxillofacial patients
The bone substitute Coll/Pro Osteon 200, compared with other bio-
materials, gave remarkable aesthetic results, in terms of naturalness
and symmetry. These data allowed us to give high VAS scores to
patients.9 A 3-year clinical study was performed to evaluate the long-
term results of new bone formation in patients (n = 50) who
underwent malar augmentation during orthognathic surgical proce-
dures. The imaging data collected at 1 month after surgery
(T1) showed that the prosthesis maintained their granular structure,
without evidence of HA granules migration into the surrounding soft
tissues (Figure 6A). This result gives evidence of biomaterial physical
stability. Stability of implants volume was also observed. In agreement
F IGURE 3 Osteogenic markers
in human adipose mesenchymal
stem cells (hASCs) cultured on the
biomaterial. A, Alizarin red staining
at day 40 is shown in the panel, in
experimental conditions tested.
Scale bar: 50 μm, Magnification
×4. B, Alkaline phosphatase (ALP)
activity at day 40. Scale bar: 50 μm,
Magnification ×4. C, The matrix
mineralization was evaluated by
Alizarin red staining, whereas its
quantification was carried out
spectrophotometrically. Matrix
mineralization data were reported
as optical density. Data are shown
in the graph. D, The temporal
pattern of osteocalcin (OCN)
protein levels detected at different
time points, that is, at days 14, 21,
and 40, was quantified by ELISA.
Osteocalcin protein was reported
as nanograms of OCN/1 μg of total
protein. E, Detection of C-type
lectin domain family 3, member B
(CLEC3B) protein by
immunostaining in hASCs, at day
40. Symbols indicate statistical
significance (*P < .05; **P < .0001).
Scale bar: 50 μm,
Magnification ×40
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with findings of earlier studies, the size of prosthesis appeared to be
stable over time after an initial moderate decrease in volume during
the first 18 months.9 The prosthesis structure was radiotransparent
compared with the compact aspect of the zygomatic bone. At
24 months after surgery (T2), the prosthesis seemed to adhere
staunchly to the underlying zygomatic bone in all patients (Figure 6B).
The granular structure was still distinguishable, although less evident
if compared with the previous healing period. The partial
F IGURE 4 Stem cell viability and cytoskeleton architecture assays. A, Human adipose mesenchymal stem cell (hASC)-eGFP grown on the
biomaterial at days 14, 21, and 40 are shown at magnification ×40. B, hASC-eGFP grown on the biomaterial at days 14, 21, and 40 are shown at
magnification ×20. C, Cytoskeleton analysis by Phalloidin tetramethyl-rhodamine-isothiocyanate (TRITC) staining of hASCs grown on the
biomaterial. Actin filaments do not show alteration in the structural organization, confirming the compatibility of the assayed biomaterial, at days
14, 21, and 40 (magnification ×40). D, Cytoskeleton analysis carried out by the confocal microscopy at day 40, magnification ×40. E, Cytoskeleton
analysis by phalloidin TRITC staining of hASCs-eGFP grown on the biomaterial, at days 14, 21, and 40 (magnification ×40). Cellular nuclei were
stained with 0.5 mg/mL DAPI
F IGURE 5 Scanning electron microscopy analysis of the Coll/Pro Osteon 200. A, Bovine collagen fibrils from Avitene Microfibrillar Collagen
Hemostat were mixed with Granular Pro Osteon 200 to generate the scaffold Coll/Pro Osteon 200. The biomaterial shows the porous structure
with several pores in the range 190 to 230 μm, Scale bar: 100 μm, ×86. B-E, Human adipose derived stem cells (hASC) grown on HA-derived
scaffold for 40 days. The structure of scaffold was observed at different magnification, Scale bar: 100 μm, ×133 (B), Scale bar: 100μm, ×214 (C),
Scale bar: 100 μm, ×344 (D), Scale bar: 20 μm, ×647 (E), respectively. F, Cells, homogeneously spread on the substrate, exhibited cytoplasmic
bridges, whereas their morphology did not show any sort of alteration. Scale bar: 2 μm, magnification ×6.55k
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radiotransparency evolved to a radiopacity, similar to that observed in
the compact part of the native bone, making it impossible to distin-
guish the interface between the prosthesis and bone (Figure 6B). At
36 months after surgery (T3), that tendency continued in agreement
to the imaging data, toward progressive loss of definition of the gran-
ular architecture and an almost complete radiopacity and apparent
corticalization of the bone in contact with the prosthesis. The inter-
face between the prosthesis and bone at T3 appeared indistinguish-
able (Figure 6C).
Histological analysis on bone specimens, harvested from three
patients requiring plate device removal 2 years after surgery, was
carried out. The persistence of porous HA scaffold and macro-
phages, although without inflammatory infiltrate, was found in
samples. In analyzed fields, fibrous stroma was revealed in 50% of
the biopsies, whereas new osteogenesis and mature bone was
found in 70% of these specimens (Figure 6D). Immunohistochemi-
cal investigations uncovered some cathepsin K protease contained
in the cytoplasm of the macrophages, thus indicating the presence
of osteoclast activity localized around HA granules (Figure 6D).
The anti-CD56 antibodies indicated a higher amount of new bone
formation at the side of the biopsy sample adjacent to the native
bone (deep), confirming the results of histomorphometric analyses
(data not shown). Specifically, in agreement with the biopsy data,
the presence of mature bone was found prominently at the perios-
teal side, whereas the presence of new immature bone was
detected entirely on the deep layer of the native bone with a bone
F IGURE 6 Scaffold characterization in patients: radiologic and histologic analyses. A-C, Cone-beam tomogram, coronal slice, at T1 (1 month),
T2 (24 months), and T3 (36 months) after surgery. A, The prosthesis maintained its granular structure, whereas the granules did not migrate to the
surrounding soft tissues. The structure of the prosthesis is radiotransparent compared with the compact portion of the zygomatic bone (T1). B,
Cone-beam tomogram, coronal slice, at 24 months after surgery. The prosthesis seems to adhere strongly to the underlying zygomatic bone in
patients. The granular structure is still distinguishable, although less evident, whereas the partial radiotransparency evolved to a radiopacity
similar to that seen in the compact part of the native bone, making it impossible to distinguish the interface between the prosthesis and bone. C,
Cone-beam tomogram, coronal slice, at 36 months after surgery. Progressive loss of definition of the granular architecture, with an almost
complete radiopacity and apparent corticalization of the bone in contact with the prosthesis. The interface between the prosthesis and bone at
T3 appears indistinguishable. D, Biopsies harvested 24 months after implant placement. Bone maturation gradient can be observed proceeding
from the periosteal layer toward the native bone (hematoxylin and eosin stain: magnification ×10). Osteoclasts surrounding hydroxylapatite
residual granules (immunohistochemistry with cathepsin K (magnification ×20)
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maturation gradient proceeding from the periosteal to the
deep side.
4 | DISCUSSION
The HA-Coll hybrid scaffold was evaluated using an in vitro cellular
model consisting of primary hASCs and a cohort of maxillofacial
patients for its osteoinductivity and biocompatibility proprieties and
bone regrowth. Epigenetic analyses carried out in 84 genes of the
osteogenetic pathway, in hASCs grown on biomaterial, indicate that
among DEGs BMP2 is induced and upregulated. Accumulating studies
proved that BMP-2 is involved in bone formation, bone remodeling,
bone development, and osteoblast differentiation.31,32 BMP-2,
belonging to the BMPs family, is a potent osteoinductive cytokine
from the transforming growth factor beta (TGF-β) family, and it is cur-
rently the most commonly used protein-based bone graft substitute.33
Recombinant human bone morphogenetic protein 2 (rhBMP-2), in
human amnion MSCs, with nano-HA/Coll/poly (L-lactide), provides a
potential approaches in tissue engineering for periodontal bone
regeneration.31 Furthermore, in vitro and in vivo results using a rat
cranial bone defect model demonstrated that the 3D nanofibrous
scaffolds incorporated with nano-hydroxylapatite (nHA) and BMP-2
peptides exhibited favorable biocompatibility and osteoinductivity.34
In addition, the DEG analysis performed by RT2 Profiler PCR array
allowed us to detect early epigenetic modifications induced in hASCs
by scaffold.
In our experiments, the biomaterial modulated ALP gene expres-
sion at mRNA level and its enzymatic activity. ALP is a bone-specific
alkaline phosphatase synthesized by the osteoblasts, whereas it is
involved in the calcification of bone matrix.
DEGs include the beta-GLAP gene encoding for the OCN. OCN
expression profile and polypeptide correlated with the mRNA and
protein levels. Indeed, ELISA data show a statistically significant
increase of the OCN in cells grown on biomaterial, at the three time
points, that is, at days 14, 21, and 40, compared with the control.
The expression profiles of other osteogenic proteins were not
analyzed.
EGFR, which plays important roles in osteogenesis, was
upregulated by the biomaterial, up to day 40. EGFR signaling pathway
is an important bone regulator, whereas it primarily plays an anabolic
role in bone metabolism. The suppression of the IGF-1R/mTOR-
pathway by the EGFR/ERK/IGFBP-3 signaling is necessary to balance
the osteoblast differentiation/maturation providing a mechanism for
the skeletal phenotype observed in EGFR-deficient mice.35 EGFR sig-
naling is important for maintaining osteoprogenitor population at an
undifferentiated stage reducing the expression of two major osteo-
blastic transcription factors, Runx2 and SP7/Osterix, in osteoblast dif-
ferentiating cells.36 Runx2 and SP7 are transcription factors necessary
for bone formation and responsible for controlling the differentiation
of MSCs in osteoblasts.37,38 In our experiments the expression of
transcription factors Runx2 and SP7 was upregulated up to day
21, whereas it was not upregulated at day 40. It is possible that the
continuous activation of EGFR in undifferentiated osteoprogenitor
cells grown on scaffold could attenuate the expression of SP7 and
Runx2, found upregulated only at day 21. SPP1 gene that codifies for
the osteopontin was modulated by the biomaterial. Osteopontin pro-
tein is considered to play an important role in bone regrowth, as
well.39
Among DEGs, modulated by the biomaterial, there are BMPR1b
and SOX9. The knockdown of BMPR1b by siRNA inhibited the osteo-
genic differentiation of human bone marrow-derived mesenchymal
stem cells40; BMPRIB appears primarily expressed in mesenchymal
precartilage condensations, in differentiated osteoblasts and cho-
ndrocytes.41 Sox9 is a transcription factor that plays a key role in cho-
ndrogenesis, by controlling the expression of type II collagen and
aggrecan, as well as by supporting chondrocyte survival and hypertro-
phy.42 It seems essential for chondrocyte differentiation.
Quantitative reverse transcriptase-polymerase chain reaction rev-
ealed an increased expression of the RANKL, also known as tumor
necrosis factor ligand superfamily member 11 (TNFSF11) with an FC
(Log2) of 4.36 and FC 4.87 at days 21 and 40, respectively. During
the process of the physiological bone remodeling RANKL, the main
osteoclastic effector, is expressed in a membrane-bound form on
many mesenchymal cells including MSCs, osteoblasts, osteocytes, and
chondrocytes.43 To maintain normal bone homeostasis, RANKL signal-
ing must be properly regulated.43 Downregulated genes were those
that encode for (i) cell-to-cell adhesion, such as VCAM1 and COMP,
(ii) cell ECM adhesion, such as CD36, ITGAM. These molecules may
play a role in the remodeling of the ECM and formation of new histo-
logical structures. Interestingly, VCAM1 is continuously down-
regulated up to day 40.
In hASCs grown on biomaterial CLEC3B protein was found to be
expressed up to day 40. CLEC3B protein, which binds Ca2+, was investi-
gated because of its potential involvement in the bone mineral metabo-
lism. In hASCs CD105-enriched cell populations, an increased CLEC3B
expression was detected in response to osteoinduction.30 In a previous
study, we reported that hASCs grown on the biomaterial, in an early
phase at days 3 and 9, upregulated specific genes involved in bone min-
eralization and ossification processes.17 It is worth recalling that the oste-
oinductive activity of the biomaterial is highlighted by the matrix
mineralization detected in hASCs grown on the scaffold, up to day 40.
hASC-eGFP morphology was indistinguishable from parental
hASCs. The cytoskeleton architecture seemed to be well organized,
whereas its integrity remains uninfluenced by the biomaterial, up to
day 40. In addition, SEM analysis carried out on scaffold showed a dif-
ferent histologically bone-like structure when observed without and
with cells grown on it, up to day 40. This difference could depend on
the cell matrix produced and released on the scaffold.
The hybrid scaffold used in vivo had a successful outcome in
patients, demonstrated by a significant osteogenic induction. The
radiologic findings confirmed that the prosthetic material changes
over time; initially, it is radiotransparent with a granular structure but
over time shows increasing uniformity and radiopacity, which presup-
poses that the material has been resorbed and replaced by cortical
bone. In a follow-up of 36 months after surgery, the radiologic
386 MAZZONI ET AL.
evaluation showed an almost complete radiopacity and apparent
corticalization of the bone in contact with the prosthesis in maxillofa-
cial patients. The expression of protein CD56 indicated a higher
amount of new bone formation at the side of the biopsy sample adja-
cent to the native bone. According to biopsy findings, the presence of
mature bone was found preeminently at the periosteal side, whereas
the presence of new immature bone was detected entirely on the
deep layer of the native bone. CD56 protein in the newly formed
bone of maxillofacial patients was in agreement with osteogenic
genes found to be upregulated in cellular model of stem cells. The
expression of cathepsin K protease contained in the cytoplasm of the
macrophages, thus indicating the presence of osteoclast activity local-
ized around HA granules.
Previous studies reported that the pivot role, for hASCs osteogenic
differentiation, is played by the HA,44-47 whereas the collagen mainly
supports the survival, proliferation, and chondrogenic differentiation.48,49
5 | CONCLUSION
Important biological processes, underlying the continuous supply of
hASCs for bone remodeling, were the osteoblastic, chondrogenic, and
osteoclastic inductions stimulated by HA-Coll hybrid scaffold in
patients. In conclusion, the hybrid scaffold investigated herein seems
to be an excellent biomaterial able to drive bone regrowth and remo-
deling. This performance is due to Coll/Pro Osteon characteristics
which allow to enhance in hASCs the adhesion, morphology, and pro-
liferation, while inducing upregulation of osteogenic genes with
improving matrix mineralization and cell viability.
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